Bone Sialoprotein and the Paradox of Angiogenesis Versus Atherosclerosis

Chunming Dong, Pascal J. Goldschmidt-Clermont

Bone sialoprotein (BSP) is a protein thought to be highly specific for bone. BSP contains an arginine-glycine-aspartic acid (RGD) cell attachment sequence involved in osteoclast adhesion to bone matrix via the vitronectin receptor and plays an important role in the early process of bone mineralization and resorption. The study by Bellahcene et al.1 in this issue of Circulation Research indicates that BSP mediates adhesion and chemotactic migration of endothelial cells and promotes angiogenesis, suggesting that BSP may be an important factor in angiogenesis and the initiation of atherosclerosis, two processes that are probably related.

In earlier studies, Folkman2 hypothesized that tumor growth beyond a few millimeters requires recruitment and growth of a new microcirculation, or angiogenesis, which is induced by tumors as lifelines for oxygen and nutrients. New blood vessels also provide exit for cancer cells to spread to other parts of the body. Angiogenesis is also involved in physiological conditions, such as embryogenesis, and other pathological conditions, such as wound healing. The process of angiogenesis requires a highly coordinated series of events, including endothelial cell proliferation, migration, tube and lumen formation, and, in some cases, recruitment of smooth muscle cells (SMCs) and adventitial cells.

Adhesive interaction of cells with components of the extracellular matrix is a recognized requirement for cell proliferation and migration. Evidence indicates that many of the adhesive interactions are mediated by members of the integrin family of heterodimeric adhesion receptors. Among these integrins, αβ3, which is expressed by a variety of cell types, has been shown to play a key role in the cell migration involved in metastasis and angiogenesis.3 The work presented by Bellahcene et al.1 indicates that BSP, a bone-associated protein that contains the RGD sequence, a common recognition sequence for most integrins, binds αβ3 in endothelial cells and mediates the migration of such cells, extending the study by Byzova et al.4 Furthermore, Bellahcene et al.1 show that another integrin, αβ5, does not bind BSP, suggesting that there is a certain degree of specificity for the interaction between BSP and αβ3.

The in vivo data indicating that BSP promotes angiogenesis via its interaction with αβ3 integrin and that such an angiogenic effect is probably even greater than that of basic fibroblast growth factor (bFGF)5 are intriguing. These data underscore the physiological and pathophysiological consequences of the interaction between BSP and αβ3 integrin and define BSP as a novel angiogenic factor. These findings may provide an explanation for the previously established association of BSP expression levels in tumors with the development of bone metastases.6 Higher BSP expression in the tumor correlates with an increased risk of metastasis of carcinomas to bone tissue, which could be due to angiogenesis enhancement by BSP. In addition, BSP expression in the tumor may facilitate tumor cell migration and calcification.

Several families of factors have been implicated in angiogenesis. These include angiogenic factors, such as vascular endothelial growth factor (VEGF) or bFGF, and antiangiogenic factors, such as angiostatin or endostatin.6 Translational research has now been initiated by several centers to test the hypothesis that local delivery of angiogenic agents, especially VEGF and bFGF, by various strategies, including viral vectors, naked DNA, or purified recombinant proteins, may improve blood flow to ischemic tissues in patients with advanced atherosclerosis.7 Similarly, clinical trials for local delivery of antiangiogenic factors, such as angiostatin, using various techniques, are underway to treat patients with malignant tumors.8 Although blockade of BSP interaction with αβ3 may limit tumor growth and metastasis, the effect of local delivery of BSP to improve blood flow to ischemic tissues, in particular the myocardium, may be complicated by the fact that BSP-αβ3 interaction may also initiate and aggravate atherosclerosis.

Neoointima formation, associated with both atherosclerosis and restenosis, is a complex process that involves SMC migration and proliferation. The molecular mechanisms governing intimal thickening have been a focus of intense research. Numerous studies have indicated a critical role for integrin heterodimers, including αβ3, in mediating cell-matrix interactions and SMC adhesion and migration, implicating the potential involvement of physiological ligands containing RGD sequence, including BSP, for the activity of such integrins.9 Indeed, in vitro studies have shown that osteopontin, a bone-associated protein closely related to BSP, which contains the RGD sequence, supports SMC adhesion to αβ3. αβ5, and αβ3 integrins and mediates SMC migration specifically via αβ3.9 In vivo experiments have demonstrated that osteopontin and αβ3 are expressed in vascular SMCs. In addition, osteopontin expression is upregulated in human atherosclerotic and restenotic lesions.10 Using animal models of neointima formation, several groups have observed increased expression of osteopontin and αβ3 in such lesions.11 More direct evidence supporting the potential...
role of osteopontin in the process of intimal thickening stems from the observation that neutralizing antibodies to osteopontin limit neointimal thickening in rat carotid artery after balloon injury.\textsuperscript{12} RGD and \( \alpha_\beta_3 \) antagonists have been shown to inhibit neointima formation in rabbit, hamster, porcine, and guinea pig vascular injury models, an effect that has been interpreted to be mediated via the disruption of osteopontin–\( \alpha_\beta_3 \) interaction.\textsuperscript{13,14} The data presented by Bellahcene et al.\textsuperscript{1} showing that BSP interaction mediates endothelial cell adhesion and migration, implicate the potential role for BSP in atherosclerosis. It is probable that BSP–\( \alpha_\beta_3 \) interaction is disrupted by RGD and \( \alpha_\beta_3 \) antagonists, which may account for, at least in part, the antiatherogenic effect exerted by these agents in the in vivo experiments. Characterization of BSP–\( \alpha_\beta_3 \) interaction and such interaction-induced adhesive and migratory effect on SMCs, examination of BSP expression in vascular lesions, and the use of neutralizing antibodies to BSP in animal models will help clarify the putative role of BSP in the initiation of atherosclerosis and may provide a therapeutic alternative to vascular disease.

Calcification associated with atherosclerotic plaques has been increasingly recognized as an active, regulated process that contributes to the fate of the atherosclerotic plaque, including rupture and subsequent thrombosis.\textsuperscript{15} However, the molecular determinants regulating extracellular matrix calcification have yet to be identified. Several studies have shown that noncollagenous bone matrix proteins related to BSP, such as osteonectin, osteocalcin, and osteopontin, are found in atherosclerotic vessels and may regulate dystrophic calcification.\textsuperscript{16} A recent study has shown that BSP is expressed together with osteonectin, osteocalcin, and osteopontin by vascular pericytes.\textsuperscript{17} Further study is required to examine the expression of BSP and its spatial relationship with early calcification in atherosclerotic plaques to establish the role for BSP in vascular calcification.

The elegant study by Bellahcene et al\textsuperscript{1} reveals a novel function of BSP as an angiogenic factor. It also opens new research venues to study the role of BSP in the initiation and calcification of atherosclerosis. The relationship between BSP as an angiogenic factor and a factor promoting atherosclerosis or neointimal hyperplasia does not appear to be unique to BSP. It has been shown that microvessels within the advanced atherosclerotic lesions have a high level of VEGF expression. Moreover, intense VEGF expression is noted in totally occlusive lesions with extensive neovascularization.\textsuperscript{18} The angiogenic factor bFGF may incite, in some instances, aggressive vascular neointimal proliferation.\textsuperscript{19} Furthermore, anti-angiogenic factors can reduce substantially neointimal formation in animal models of atherosclerosis.\textsuperscript{20} The dual role of molecules implicated in angiogenesis and atherosclerosis stresses the challenge to scientists seeking a way to promote angiogenesis for ischemic tissues. The success of such efforts will likely require the fine characterization of molecular pathways involved in both angiogenesis and atherosclerosis. Until these pathways are characterized, one might be concerned about progression of atherosclerosis when using angiogenic factors such as BSP, VEGF, or bFGF to treat ischemic heart disease. Although the participation of factors in processes like angiogenesis and atherosclerosis may appear paradoxical, our evolving understanding of advanced atherosclerosis as a misguided form of angiogenesis provides a new target for the design of therapeutic strategies.

References


Key Words: bone sialoprotein – \( \alpha_\beta_3 \); angiogenesis – atherosclerosis
Bone Sialoprotein and the Paradox of Angiogenesis Versus Atherosclerosis
Chunming Dong and Pascal J. Goldschmidt-Clermont

Circ Res. 2000;86:827-828
doi: 10.1161/01.RES.86.8.827

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/86/8/827

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/